Literature DB >> 30141960

Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.

Paul T Elkington1, Adrian C Bateman1, Gareth J Thomas1, Christian H Ottensmeier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30141960      PMCID： PMC6290953          DOI： 10.1164/rccm.201807-1250LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  10 in total

1.  Gene Expression Signatures in Tuberculosis Have Greater Overlap with Autoimmune Diseases Than with Infectious Diseases.

Authors:  Kalum Clayton; Marta E Polak; Christopher H Woelk; Paul Elkington
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

2.  Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis.

Authors:  Eszter Lázár-Molnár; Bing Chen; Kari A Sweeney; Emilie J Wang; Weijun Liu; Juan Lin; Steven A Porcelli; Steven C Almo; Stanley G Nathenson; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

3.  The prognosis of a positive tuberculin reaction in childhood and adolescence.

Authors:  G W Comstock; V T Livesay; S F Woolpert
Journal:  Am J Epidemiol       Date:  1974-02       Impact factor: 4.897

Review 4.  Cracking the Vaccine Code in Tuberculosis.

Authors:  Maziar Divangahi; Marcel A Behr
Journal:  Am J Respir Crit Care Med       Date:  2018-02-15       Impact factor: 21.405

5.  CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition.

Authors:  Daniel L Barber; Katrin D Mayer-Barber; Carl G Feng; Arlene H Sharpe; Alan Sher
Journal:  J Immunol       Date:  2010-12-20       Impact factor: 5.422

Review 6.  Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.

Authors:  Vassiliki A Boussiotis
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

Review 7.  Permutations of time and place in tuberculosis.

Authors:  Paul T Elkington; Jon S Friedland
Journal:  Lancet Infect Dis       Date:  2015-08-28       Impact factor: 25.071

8.  Tuberculosis: An Infection-Initiated Autoimmune Disease?

Authors:  Paul Elkington; Marc Tebruegge; Salah Mansour
Journal:  Trends Immunol       Date:  2016-10-21       Impact factor: 16.687

Review 9.  The immune response in tuberculosis.

Authors:  Anne O'Garra; Paul S Redford; Finlay W McNab; Chloe I Bloom; Robert J Wilkinson; Matthew P R Berry
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

Review 10.  Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.

Authors:  Alimuddin Zumla; Martin Rao; Robert S Wallis; Stefan H E Kaufmann; Roxana Rustomjee; Peter Mwaba; Cris Vilaplana; Dorothy Yeboah-Manu; Jeremiah Chakaya; Giuseppe Ippolito; Esam Azhar; Michael Hoelscher; Markus Maeurer
Journal:  Lancet Infect Dis       Date:  2016-04       Impact factor: 25.071
  10 in total
  15 in total

Review 1.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

2.  Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.

Authors:  Gregory R Stroh; Tobias Peikert; Patricio Escalante
Journal:  Cancer Immunol Immunother       Date:  2021-03-26       Impact factor: 6.968

3.  Reconsidering the Optimal Immune Response to Mycobacterium tuberculosis.

Authors:  Liku B Tezera; Salah Mansour; Paul Elkington
Journal:  Am J Respir Crit Care Med       Date:  2020-02-15       Impact factor: 21.405

Review 4.  Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations.

Authors:  Amalia Anastasopoulou; Dimitrios C Ziogas; Michael Samarkos; John M Kirkwood; Helen Gogas
Journal:  J Immunother Cancer       Date:  2019-09-04       Impact factor: 13.751

5.  Long-term remission of small cell lung cancer after reactivation of tuberculosis following immune-checkpoint blockade: A case report.

Authors:  Mattia Sirgiovanni; Clemens Hinterleitner; Marius Horger; Naushad Bijoy Atique; Ulrich M Lauer; Lars Zender; Martina Hinterleitner
Journal:  Thorac Cancer       Date:  2021-01-17       Impact factor: 3.500

Review 6.  The dark side of immunotherapy.

Authors:  Nwanneka Okwundu; Douglas Grossman; Siwen Hu-Lieskovan; Kenneth F Grossmann; Umang Swami
Journal:  Ann Transl Med       Date:  2021-06

Review 7.  Immune Checkpoint Inhibitors in Special Populations.

Authors:  Qianyun Shan; Hongyang Lu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

8.  The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis.

Authors:  Mei Chai; Qingming Shi
Journal:  BMC Cancer       Date:  2020-11-19       Impact factor: 4.430

9.  Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy.

Authors:  Yada Kanjanapan; Desmond Yip
Journal:  Cancer Med       Date:  2020-11-07       Impact factor: 4.452

10.  Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α.

Authors:  Liku B Tezera; Magdalena K Bielecka; Paul Ogongo; Naomi F Walker; Matthew Ellis; Diana J Garay-Baquero; Kristian Thomas; Michaela T Reichmann; David A Johnston; Katalin Andrea Wilkinson; Mohamed Ahmed; Sanjay Jogai; Suwan N Jayasinghe; Robert J Wilkinson; Salah Mansour; Gareth J Thomas; Christian H Ottensmeier; Alasdair Leslie; Paul T Elkington
Journal:  Elife       Date:  2020-02-24       Impact factor: 8.140
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.